No. 1
$70M
Amount raised
Ratio Therapeutics
Series C·biotech·USA
Ratio Therapeutics is Clinical-stage pharmaceutical company developing radiopharmaceuticals for cancer treatment.
Ratio Therapeutics closed a $70M Series C to advance its ATLAS trial for targeted radiotherapeutics and expand manufacturing capabilities. The round was led by Duquesne Family Office, with participation from Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company.
